Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

Gumus, MahmutChen, Chieh-IIvanescu, CristinaKilickap, SaadettinBondarenko, IgorOzguroglu, MustafaGogishvili, MirandaTurk, Haci M.Cicin, IrfanHarnett, JamesMastey, VeraNaumann, UlrikeReaney, MatthewKonidaris, GerasimosSasane, MedhaBrady, KeriLi, SiyuGullo, GiuseppeRietschel, PetraSezer, Ahmet2021-11-302021-11-302021-05-01Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., Gogishvili M., Turk H. M. , Cicin I., Harnett J., et al., -Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021http://hdl.handle.net/20.500.12645/29674Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.ArticleWOS:00070812060505810.1200/jco.2021.39.15_suppl.9078